Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Xellia has added a 500mg/100ml variant to its range of vancomycin ready-to-use bags in the US, while Kabi has introduced ertapenem 1g vials and struck a critical-care supply deal with Vizient.
Rather than blame employees for ignoring 397 product complaints, Teligent should have fixed complaint handling system, US FDA warning letter says.
Patent litigation settlements have paved the way for Endo’s Par and Teva to secure the first US approvals for generic versions of Novartis’ Afinitor everolimus brand.
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.
A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.